[ad_1]
The results are based on a blood test from those who participated in the trials conducted in Germany, based on a more comprehensive analysis than the results published last week.
Last week, a laboratory result announced by Pfizer and BioNTech in the US showed that the vaccine was effective against the key mutation N501Y, which is found in both the new highly infectious mutations that have emerged in the UK and in South Africa.
The latest study, which has not yet been reviewed by the reviewer, was conducted on 10 mutations that are characteristic of the variant known as B117 identified in England.
It was announced that the vaccine called “BNT162b2” developed by the US pharmaceutical company Pfizer and the German biotechnology company BioNTtech provides protection against the new mutated species of coronavirus. Pfizer / BioNTech has published data that the “BNT162b2” vaccine provides protection against the “B117” mutation virus that first appeared in the UK.
BioNTech stated that they compared the mutation virus that emerged in the UK to effectiveness against the pathogenic form of the virus that emerged in Wuhan, China.
class = “cf”>
In the statement, it was stated that there was no significant difference in the effectiveness of the antibodies as a result, the neutralizing antibodies recognized and neutralized the new type of virus. Furthermore, it was claimed that as a result of the research, the vaccines were also found to provide protection against the mutation.
THESE NEWS MAY BE INTERESTED
